Discovery of a Selective S1P(1) Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate

[Image: see text] Gilenya (fingolimod, FTY720) was recently approved by the U.S. FDA for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). It is a potent agonist of four of the five sphingosine 1-phosphate (S1P) G-protein-coupled receptors (S1P(1) and S1P(3−5)). It has be...

詳細記述

保存先:
書誌詳細
主要な著者: Demont, Emmanuel H., Andrews, Benjamin I., Bit, Rino A., Campbell, Colin A., Cooke, Jason W. B., Deeks, Nigel, Desai, Sapna, Dowell, Simon J., Gaskin, Pam, Gray, James R. J., Haynes, Andrea, Holmes, Duncan S., Kumar, Umesh, Morse, Mary A., Osborne, Greg J., Panchal, Terry, Patel, Bela, Perboni, Alcide, Taylor, Simon, Watson, Robert, Witherington, Jason, Willis, Robert
フォーマット: Artigo
言語:Inglês
出版事項: American Chemical Society 2011
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4018134/
https://ncbi.nlm.nih.gov/pubmed/24900328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml2000214
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料